Nodality, Inc. today announced a strategic collaboration with Pfizer Inc. for
the use of Nodality's proprietary Single Cell Network Profiling (SCNP)
technology as a tool for the development of Pfizer compounds. The agreement
establishes a multi-year, collaborative effort that will initially focus on
providing biological bases for streamlining the development of potential
Pfizer compounds for autoimmune disease with an initial focus on Lupus,
including characterizing mechanisms of action, disease analysis, and drug
profiling. The agreement also provides Pfizer the option to engage Nodality in
companion diagnostics development. The terms of the agreement include an
upfront payment, R&D funding, and success-based milestone payments.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in